



A Meta-Analysis on The Comparison of The Sensitivity of Three Test Methods Used in the Diagnosis of COVID-19

Elmas Pinar Kahraman Kilbas ^{1,*}, Imdat Kilbas ² and Ihsan Hakki Ciftci ²

¹Medical Laboratory Techniques, Vocational School of Health Services, Fenerbahce University, Istanbul, Turkey

²Department of Medical Microbiology, Faculty of Medicine, Sakarya University, Sakarya, Turkey

*Corresponding author: Medical Laboratory Techniques, Vocational School of Health Services, Fenerbahce University, Istanbul, Turkey. Email: elmaspnar1@gmail.com

Received 2021 September 14; Revised 2022 January 18; Accepted 2022 January 29.

Abstract

Background: Accurate detection of the global epidemic-causing coronavirus disease 2019 (COVID-19) is for disease surveillance. Additionally, RT-qPCR has been accepted as a reference test and is widely used for this purpose. However, RT-qPCR applications are not possible in all health centers. Therefore, the tests commonly used in the diagnosis of infectious disease should be evaluated from all angles to assess their potential role in the prognosis and management of COVID-19 patients.

Objectives: The present study aimed to compare the diagnostic sensitivity of point of care (POC), enzyme-linked immunosorbent assay (ELISA), and computed tomography (CT) used in the diagnosis of COVID-19.

Methods: This systematic review and meta-analysis was conducted via searching in databases such as NCBI, Google Scholar, and Medline in accordance with the preferred reporting items for systematic reviews and meta-analysis (PRISMA).

Results: The pooled sensitivity of POC, ELISA, and CT was estimated at 68.62%, 88.05%, and 75.43%, respectively. In addition, the mean correct positivity rate of POC, ELISA, and CT was calculated to be 68.61%, 88.04%, and 79.25%, respectively. The sensitivity and true positivity rate of ELISA was observed to be the highest.

Conclusions: According to the results, ELISA is a more accurate approach to the diagnosis of COVID-19 compared to POC and CT owing to its high sensitivity and true positivity rate, low false negative rate, short processing time, and simple study procedure. Although helpful in diagnosis, confirmation of ELISA results by polymerase chain reaction remains the 'gold standard'.

Keywords: COVID-19, Point of Care Test, Enzyme-linked Immunosorbent Assay, Reverse Transcription-Polymerase Chain Reaction, Computed Tomography

1. Background

Pneumonia caused by the new coronavirus was announced as the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO) on February 11, 2020, which was taken to the epidemic scale and spread rapidly all over the world (1). Initially, the exact diagnosis of COVID-19 was possible by detecting the SARS-CoV-2 ribonucleic acid (RNA) in the specimens sent from the infected cases (2). Later, various diagnostic tests were used to identify the virus, including molecular tests such as reverse transcription-polymerase chain reaction (RT-PCR) tests, which identifies the genetic material of the virus, and antigen tests that detect special proteins on the virus surface. Today, new tests have been introduced for COVID-19 detection, which provide diagnostic benefits (3).

In order to adequately cope with the COVID-19 pandemic and remove the constraints imposed on the com-

munity, there is an urgent need for tests that can work with a minimum of devices and equipment, including at home. COVID-19 IgG/IgM antibody tests are used for the detection of SARS-CoV-2 with quick point-of-care (POC) tests. POC diagnostic test methods are rapid and use a mucus sample from the nose or throat. As such, POC tests that are scalable, cost-effective, and easy to use are critical to battle COVID-19 (4).

Optimized enzyme-linked immunosorbent assay (ELISA) is used in numerous clinical virology laboratories for diagnostic purposes and evaluating conditions such as infections, vaccination, and re-infection (5, 6). Most of the antibodies reported for SARS-CoV-2 have been used for ELISA (7). Furthermore, serological tests for the detection of SARS-CoV-2 are under development. Zhang et al. determined IgG and IgM positivity from COVID-19 patient sera using the N protein-specific ELISA test (8).

In the study conducted by Huang et al., the results of

the unenhanced computed tomography (CT) of 41 patients with definite COVID-19 were published as the first article in this regard (9). Following that, scientific publications on the diagnosis of COVID-19 increased, and the clinical indications for chest CT are constantly changing. Although RT-PCR is the 'gold standard' diagnostic test for confirming the diagnosis of COVID-19, it could be a valuable guide in the initial assessment of non-contrast chest CT patient populations (10).

Accurate detection of the global epidemic-causing COVID-19 is imperative for disease surveillance and control. Dozens of tests have been made available within a short time for COVID-19 diagnosis. With the rapid development of such tests, rigorous evaluations have become difficult, and there are important uncertainties regarding the specificity of these tests. Quantitative RT-qPCR has been accepted as a reference test and is widely used for COVID-19 diagnosis. However, RT-qPCR applications are not possible in all health centers. Therefore, tests with widespread use in the diagnosis of infectious disease should be evaluated from all perspectives to assess their potential role in the prognosis and management of COVID-19 patients (2). Our study is of particular importance as it clarifies the mentioned situation.

2. Objectives

This meta-analysis aimed to compare the diagnostic sensitivity of POC, ELISA, and CT tests in the diagnosis of COVID-19 infection, evaluate the quality of the existing tests, and compare the PCR-verified sensitivity of these test methods.

3. Methods

3.1. Protocol and Registration

The preferred reporting items for systematic reviews and meta-analysis (PRISMA) protocol was used for this review. The focus of the review was the comparison of the sensitivity of the diagnostic methods used for COVID-19.

3.2. Search Strategy

This meta-analysis was conducted via searching in databases such as NCBI, Google Scholar, and Medline for studies published in English in 2020. Subject headings/sub-headings were used for the COVID-19/SARS-CoV-2 and the POC, ELISA, and CT tests. The literature review applied to publications during January 1, 2020-November 15, 2020. We also evaluated the articles included in the references of other studies (Figure 1).

3.3. Eligibility Criteria

The eligibility criteria of our study were clinical researches reporting the sensitivity of POC, ELISA, and CT in COVID-19 diagnosis. Review studies, letters to the editor, case reports, modeling/economic studies, articles with a smaller sample size than 50, studies lacking clear data, and those not comparing the mentioned test methods with PCR were excluded.

3.4. Study Selection

Articles were searched using keywords in the literature search via Google Scholar, NCBI, and Medline. At this stage, we collected the articles identified in these databases, and the articles that did not meet the inclusion criteria were excluded. Following that, the full texts of the eligible articles were retrieved and reviewed independently. Disagreements between the authors were resolved by scientific consensus. In this meta-analysis, we selected the studies that compared the sensitivity rate of the test methods used for COVID-19 diagnosis with a reference RT-PCR standard. Clinical trials conducted on 50 or more patients reporting the sensitivity of POC, ELISA, and CT for COVID-19 diagnosis were selected and reviewed.

3.5. Quality Assessment

Table 1 shows the methodological evaluation of the study. Notably, these quality criteria were not considered as exclusion criterion. The qualitative review of the selected studies for the meta-analysis was scored based on a checklist designed with critical evaluation by three independent researchers. These criteria were the applied test method, number of the included patients, and the false negative and true positive rates of the applied tests (Table 1).

Table 1. The Criteria Set for the Quality Evaluation of Studies

| | 3 Points | 2 Points | 1 Point |
|-------------------------------------|----------|-----------|---------|
| Test method | ELISA | CT | POC |
| No. of patients | > 500 | 100 - 500 | < 100 |
| False-negative rate of used test, % | < 10 | 10 - 30 | > 30 |
| True-positive rate of used test, % | > 80 | 50 - 80 | < 50 |

3.6. Data Extraction

One of the researchers extracted the aggregated data using a standard electronic data entry form. For each study, the second and third investigators validated the entered data. Duplicate data were not found, and data were




Figure 1. Screening studies for meta-analysis

collected on trace characteristics (country, sample type, applied method) and the methodological details regarding the index and reference.

3.7. Statistical Analysis

Data analysis was performed in SPSS version 25 and comprehensive meta-analysis (CMA) using one-way ANOVA and paired sample *t*-test, which were performed in SPSS. The effect sizes and heterogeneity (I^2 and Q) of the selected studies were calculated in CMA, and a forest plot was used to assess publication bias. Heterogeneity in meta-analysis refers to variations in the results of the selected studies. The thresholds for the interpretation of I^2 could be misleading as the significance of the discrepancy depends on

several factors. A rough guide to such interpretation is as follows:

- 0 - 40%: may not matter;
- 30 - 60%: may represent moderate heterogeneity;
- 50 - 90%: may represent substantial heterogeneity;
- 75 - 100%: significant heterogeneity

3.8. Data Report

In the first part of our analysis, we estimated the sensitivity of POC, ELISA, and CT test methods and categorized the studies based on their applied tests methods. In several studies, researchers evaluated the accuracy of multiple test methods simultaneously (eg, POC and ELISA). For the index test performed on each study, the required numbers to

form 2×2 probability tables were extracted. Each assessment of a particular index test was considered as the arm of the study. For instance, a study performing two ELISA and three CT evaluations on the same patient group would contribute to five study arms. It was also assumed that the sensitivity results of the tests would vary depending on the methods, countries, and sample types. As such, we classified the samples with primary results based on the applied methods, regions, and countries.

4. Results

4.1. Study Selection

The literature search yielded 7,500 studies corresponding to the keywords. After eliminating repetitive studies, 5,018 articles remained (Figure 1). In total, 48 studies that met the inclusion criteria were included, and review studies, letters to the editor, case reports, modeling/economic studies, articles without clear data, the studies with smaller sample sizes than 50, and those without a PCR comparison were excluded. Most of the studies that were selected for the meta-analysis ($n = 48$) and evaluated POC, ELISA, and CT methods were conducted in China. In the studies selected for the meta-analysis, CT was the most commonly applied method (Table 2).

4.2. Characteristics of Studies

Table 3 shows the distribution of the performed tests by country. In the studies selected for the meta-analysis, no description was provided on the sample type in 2,442 cases. However, blood and throat swabs were the most commonly used sample types in the reviewed studies. Table 4 shows the sample distribution of the performed tests on 6,305 clinical cases. In the qualitative review, the studies were scored within the range of 4-12, and the mean qualitative score of the studies was estimated at 8.16 ± 1.84 (Table 2).

4.3. Main Findings

The pooled sensitivity of POC, ELISA, and CT was estimated at 68.62%, 88.05%, and 75.43%, respectively. The mean true positive (TP) rate of POC, ELISA, and CT was reported to be 68.61%, 88.04%, and 79.25%, respectively. In addition, the mean false negative (FN) rate of POC, ELISA, and CT was calculated to be 31.38%, 11.95%, and 20%, respectively.

No significant difference was observed between the sample type and test sensitivity in one-way ANOVA ($P > 0.05$). On the other hand, a significant difference was observed between the applied method and test sensitivity (P

< 0.05). A significant difference was also denoted between the country and test sensitivity ($P < 0.05$). According to Tukey's post-hoc test, the sensitivity of ELISA and the tests performed was higher in China based on country (Table 5). However, no significant difference was observed between the sensitivity of TP in the paired-samples t -test ($P > 0.05$). A statistically significant difference was found between FN and test sensitivity. ($P < 0.05$) A statistically significant difference was found between FN (%) and test sensitivity. ($P < 0.05$) (Table 6)

The random-effect (REX) and fixed-effect (FEX) models were used to calculate the effect size of the studies. According to the effect size analysis performed at 95% confidence interval (CI), ELISA and CT studies showed substantial heterogeneity ($I^2=67.5\%$ and $I^2=85.4\%$, respectively). In addition, POC tests showed considerable heterogeneity ($I^2=94.8\%$), which was even higher than the I^2 value of the effect size of all the tests (90.2%). Table 7 shows more statistical data obtained by the FEX and REX models.

In the present study, the REX model was used to calculate the effect size of the selected studies, and a higher effect size was observed in the CT group with the REX model. In the REX model, the effect size was calculated to be 4.391 at 95% CI. According to Cohen's classification, the reviewed studies had high effect sizes. (Table 7). Figure 2 depicts each of the reviewed studies in the forest plot chart.

5. Discussion

According to the results of the current meta-analysis, the existing evidence regarding the diagnostic accuracy of POC, ELISA, and CT for COVID-19 is characterized by limitations such as high bias risks and heterogeneity. Furthermore, our findings indicated that the sensitivity of CT and POC was consistently lower compared to ELISA. The sensitivity of POC has been estimated at 68.62%, indicating a significant weakness in this test compared to marketed bedside tests for COVID-19 diagnosis.

In the present study, a significant difference was observed between the sensitivity of the tests performed in China and the sensitivity of the tests conducted in Italy. Although no significant difference was denoted between the tests in China and other countries, the sensitivity of the tests performed in China was higher compared to other countries.

In a study aiming to evaluate the ELISA kits that are commercially produced for SARS-CoV2 without completed validation or those about to be validated, the sensitivity and differences of IgA and IgG antibody titers in patient

Table 3. Summary of the Countries of the Studies Included in the Meta-analysis

| Country | Test Methods | | | | | |
|----------------------|----------------|-----------------|----------------|-----------------|----------------|-----------------|
| | POC | | ELISA | | CT | |
| | No. of Studies | No. of Patients | No. of Studies | No. of Patients | No. of Studies | No. of Patients |
| China | 2 | 102 | 9 | 1425 | 14 | 1671 |
| ABD | 3 | 159 | 1 | 40 | 1 | 141 |
| France | 0 | 0 | 0 | 0 | 1 | 572 |
| Italy | 2 | 111 | 1 | 64 | 1 | 462 |
| Jordan | 0 | 0 | 0 | 0 | 1 | 88 |
| Saudi Arabia | 0 | 0 | 0 | 0 | 1 | 150 |
| Brazil | 0 | 0 | 0 | 0 | 1 | 78 |
| Germany | 0 | 0 | 0 | 0 | 1 | 64 |
| Belgium | 0 | 0 | 1 | 94 | 0 | 0 |
| United Arab Emirates | 1 | 499 | 0 | 0 | 0 | 0 |
| India | 1 | 72 | 0 | 0 | 1 | 147 |
| Spain | 1 | 55 | 0 | 0 | 0 | 0 |
| Japan | 1 | 112 | 0 | 0 | 1 | 112 |
| Canada | 1 | 42 | 0 | 0 | 0 | 0 |
| Pakistan | 1 | 45 | 0 | 0 | 0 | 0 |
| Total | 13 | 1197 | 12 | 1623 | 23 | 3485 |

Abbreviations: POC, point of care; ELISA, enzyme linked immunosorbent assay; CT, computer tomography.

Table 4. Summary of the Sample Types Used in Studies Included in the Meta-analysis

| Sample Type | POC | | ELISA | | CT | | Total | |
|---------------------|-----|-----|-------|------|----|------|-------|------|
| | NS | NP | NS | NP | NS | NP | NS | NP |
| Unspecified | 0 | 0 | 0 | 0 | 17 | 2442 | 17 | 2442 |
| Blood | 4 | 278 | 8 | 1193 | 1 | 112 | 13 | 1583 |
| Throat swab | 0 | 0 | 1 | 63 | 2 | 652 | 3 | 715 |
| Nasal swab | 1 | 499 | 0 | 0 | 1 | 141 | 2 | 640 |
| Nasopharyngeal swab | 7 | 330 | 1 | 64 | 2 | 138 | 10 | 532 |
| Oral swab | 0 | 0 | 1 | 276 | 0 | 0 | 1 | 276 |
| Pharyngeal swab | 1 | 90 | 0 | 0 | 0 | 0 | 1 | 90 |
| Saliva-oral swab | 0 | 0 | 1 | 27 | 0 | 0 | 1 | 27 |

Abbreviations: NS, number of studies; NP, number of patients; POC, point of care; ELISA, enzyme linked immunosorbent assay; CT, computer tomography.

Table 5. Statistical Analysis of Test Sensitivity According to Various Variables (One Way ANOVA Results)

| | df | Mean Square | F | P-Value |
|-------------|----|-------------|-------|--------------------|
| Sample type | 5 | 231.431 | 0.465 | 0.800 |
| Methods | 2 | 1146.904 | 2.610 | 0.041 ^a |
| Country | 4 | 926.673 | 2.634 | 0.044 ^a |

^a P < 0.05




Figure 2. Forest plot analysis of studies in meta-analysis. (A) Forest plot analysis of CT studies in meta-analysis (11, 22, 26-35, 37-39, 41, 42, 44, 52, 54, 57). (B) Forest plot analysis of ELISA studies in meta-analysis (12, 13, 17-23, 25, 40, 55, 56). (C) Forest plot analysis of POC studies in meta-analysis (14-16, 39, 45-51, 58, 59)

Table 6. Statistical Analysis of Test Sensitivity According to Various Variables (Paired Sample t-test Results).

| | Mean \pm SD | No. | P-Value |
|--------|--------------------------|-----|--------------------|
| TP | 104.4583 \pm 133.32315 | 48 | 0.242 |
| FN | 27.2292 \pm 50.62723 | 48 | 0.001 ^a |
| FN (%) | 21.4951 \pm 20.63477 | 48 | 0.000 ^a |

Abbreviations: SD, standard deviation; TP, true positive; FN, false negative.

^a $P < 0.05$

sera were determined. According to the findings, this ELISA kit has been designed to bind to the S1 protein, and the results of IgA in the course of the disease were significantly correlated with the kit (8). Furthermore, the antibody in the kit is 90% similar to the other coronavirus N protein, indicating sufficient results and confirming the results of the serum test performed within five days from the onset of the infection by RT-PCR (60). Notably, evaluation of different recommended parameters for the course of the disease are essential to determining the specificity of SARS-CoV2 serological tests in the infection follow-up (61).

The benefits of POC tests are cost-efficiency, rapid implementation, and accurate results. However, the low sensitivity of this method is alarming. According to the studies in this meta-analysis, the sensitivity of the POC tests performed with serum/plasma samples is lower than the POC tests performed with nasopharyngeal samples; notably, the sample type should be considered in this test. Few patients are tested for suspected SARS-CoV-2 infection, and the overall results of our study may not be generalizable to all patients with suspected COVID-19.

Chest CT played a key role in the diagnosis of COVID-19 at the beginning of the outbreak and during the peak periods of the pandemic. Although RT-PCR is considered the 'gold standard' in this regard, the frequency of FN results after the first test and the absence of a laboratory kit in the early stages of the pandemic limit the early diagnosis of COVID-19 by this method. According to our findings, the tests used for the early diagnosis of COVID-19 (especially CT) have higher sensitivity in the regions that were first and heavily affected by the pandemic, such as China. Therefore, diagnostic criteria based on typical CT imaging features are only temporarily included in the current diagnostic-treatment guidelines in Hubei Province of China (62). These guidelines enable the early clinical diagnosis of COVID-19 due to the insufficiency of high-sensitivity tests such as ELISA and CT, as well as the RT-PCR diagnostic kits that contribute to the effective control of the current pandemic. The difference in this regard has

several reasons, such as differences in CT sensitivity, heterogeneity in radiologists' gaze, disease severity, and symptom onset.

Although RT-PCR is accepted as the 'gold standard', FN results are also encountered. According to Xu et al., more than 5% of COVID-19 patients initially had FN RT-PCR results, which became positive after multiple tests (63). However, 86% of these patients had positive chest CT images before their first negative RT-PCR results. Several cases of this issue are reported increasingly (62). Given the concerns about FN results, the limitations of RT-PCR, and the continued increase in the global cases of COVID-19, the British Thoracic Imaging Association highlights the importance of radiographic evaluation, especially in case of diagnostic uncertainty (64).

According to the CMA analysis in the current research, the I^2 value was 90.20%, which indicated the high heterogeneity of the selected studies for the meta-analysis ($P < 0.001$). The main reasons of the heterogeneity between the studies are the diverse number of the evaluated patients, different demographic and clinical characteristics of the patients, differences in the applied methods, mistakes of the health personnel who evaluated the diagnosis tests, differences in the tested variables in ELISA (IgG, IgM, and IgG + IgM), differences in the commercial brand of POC and ELISA kits, differences in the virus structure in immunoserological tests (surface protein, nucleocapsid protein, surface/nucleocapsid proteins), and the interval between the onset of symptoms and performing CT, ELISA, and POC.

5.1. Limitations of the Study

The main limitations of our meta-analysis were the small sample size and exclusion of the studies evaluating fewer than 50 patients. In addition, meta-regression analysis was not performed since many studies would have to be excluded due to not reporting common variables. Another limitation was that we did not search databases such as OVID, Medline, and Embase, and some published studies might have been overlooked.

5.2. Conclusions

This is the first meta-analysis to simultaneously evaluate POC, ELISA, and CT sensitivity in COVID-19 diagnosis. According to the results, these tests had different sensitivity and specificity. ELISA was considered to be a more accurate diagnostic test for COVID-19 compared to POC and CT owing to its high sensitivity and true positivity rate, low FN rate, short processing time, and simple study procedure.

Table 7. Effect Sizes and Heterogeneity Test

| Model | No. | MES | Z | 95% CI | | SD | Q | I ² | P-Value |
|--------------------|-----|-------|--------|--------|--------|----|---------|----------------|---------|
| | | | | LL | UP | | | | |
| POC | | | | | | | | | |
| FEX | 13 | 2.900 | 11.524 | 2.419 | 3.475 | NA | NA | NA | NA |
| REX | 13 | 4.074 | 3.261 | 1.751 | 9.478 | 12 | 232.050 | 94.829 | 0.000 |
| ELISA | | | | | | | | | |
| FEX | 12 | 1.188 | 2.401 | 1.032 | 1.368 | NA | NA | NA | NA |
| REX | 12 | 1.673 | 2.615 | 1.138 | 2.461 | 11 | 33.897 | 67.549 | 0.000 |
| CT | | | | | | | | | |
| FEX | 23 | 1.381 | 5.198 | 1.223 | 1.560 | NA | NA | NA | NA |
| REX | 23 | 7.963 | 7.423 | 4.604 | 13.772 | 22 | 150.752 | 85.407 | 0.000 |
| All studies | | | | | | | | | |
| FEX | 48 | 1.528 | 10.129 | 1.408 | 1.659 | NA | NA | NA | NA |
| REX | 48 | 4.391 | 8.447 | 3.115 | 6.190 | 47 | 479.700 | 90.202 | 0.000 |

Abbreviations: MES, mean effect size; REX, random effect; FEX, fixed effect; LL, lower limit; UL, upper limit; NA, non-Applicable.

Although helpful in diagnosis, confirmation of ELISA results by PCR remains the 'gold standard'. Further investigations are urgently required regarding the diagnostic performance of the test methods used worldwide for COVID-19 on larger sample sizes and in greater detail.

Footnotes

Authors' Contribution: Study concept and design: I.H.C. Acquisition of data: E.P.K.K, I.K. Analysis and interpretation of data: I.H.C, I.K. Drafting of the manuscript: I.K. Critical revision of the manuscript for important intellectual content: I.H.C. Statistical analysis: I.H.C, E.P.K.K. Administrative, technical, and material support: I.K. Study supervision: I.H.C

Conflict of Interests: None declared.

Data Reproducibility: The data presented in this study are openly available in one of the repositories or will be available on request from the corresponding author by this journal representative at any time during submission or after publication. Otherwise, all consequences of possible withdrawal or future retraction will be with the corresponding author.

Funding/Support: There was no funding/support.

References

- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-3. doi: [10.1038/s41586-020-2012-7](https://doi.org/10.1038/s41586-020-2012-7). [PubMed: [32015507](https://pubmed.ncbi.nlm.nih.gov/32015507/)]. [PubMed Central: [PMC7095418](https://pubmed.ncbi.nlm.nih.gov/PMC7095418/)].
- Togay A, Yilmaz N. [Laboratory Diagnosis of SARS-CoV-2]. *Tepecik Egit Arast Hast Dergisi*. 2020;30:70-5. Turkish.
- Li C, Zhao C, Bao J, Tang B, Wang Y, Gu B. Laboratory diagnosis of coronavirus disease-2019 (COVID-19). *Clin Chim Acta*. 2020;510:35-46.

doi: [10.1016/j.cca.2020.06.045](https://doi.org/10.1016/j.cca.2020.06.045). [PubMed: [32621814](https://pubmed.ncbi.nlm.nih.gov/32621814/)]. [PubMed Central: [PMC7329657](https://pubmed.ncbi.nlm.nih.gov/PMC7329657/)].

- Joung J, Ladha A, Saito M, Segel M, Bruneau R, Huang MW, et al. Point-of-care testing for COVID-19 using SHERLOCK diagnostics. *medRxiv*. 2020:2-21. doi: [10.1101/2020.05.04.20091231](https://doi.org/10.1101/2020.05.04.20091231).
- Xia WD, Preas C, Schnurr D. Serologic (Antibody Detection) Methods. *Clinical Virology Manual*. 50th ed. Washington DC, USA: ASM Press; 2016. p. 105-16.
- Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun*. 2020;11(1):1620-32. doi: [10.1038/s41467-020-15562-9](https://doi.org/10.1038/s41467-020-15562-9). [PubMed: [32221306](https://pubmed.ncbi.nlm.nih.gov/32221306/)]. [PubMed Central: [PMC7100515](https://pubmed.ncbi.nlm.nih.gov/PMC7100515/)].
- Infantino M, Damiani A, Gobbi FL, Grossi V, Lari B, Macchia D, et al. Serological assays for SARS-CoV-2 infectious disease: benefits, limitations and perspectives. *Isr Med Assoc J*. 2020;22(4):203-10.
- Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg Microbes Infect*. 2020;9(1):386-9. doi: [10.1080/22221751.2020.1729071](https://doi.org/10.1080/22221751.2020.1729071). [PubMed: [32065057](https://pubmed.ncbi.nlm.nih.gov/32065057/)]. [PubMed Central: [PMC7048229](https://pubmed.ncbi.nlm.nih.gov/PMC7048229/)].
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. doi: [10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- Pontone G, Scafuri S, Mancini ME, Agalbato C, Guglielmo M, Baggiano A, et al. Role of computed tomography in COVID-19. *J Cardiovasc Comput Tomogr*. 2021;15(1):27-36. doi: [10.1016/j.jcct.2020.08.013](https://doi.org/10.1016/j.jcct.2020.08.013). [PubMed: [32952101](https://pubmed.ncbi.nlm.nih.gov/32952101/)]. [PubMed Central: [PMC7473149](https://pubmed.ncbi.nlm.nih.gov/PMC7473149/)].
- Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology*. 2020;296(2):32-40. doi: [10.1148/radiol.2020200642](https://doi.org/10.1148/radiol.2020200642). [PubMed: [32101510](https://pubmed.ncbi.nlm.nih.gov/32101510/)]. [PubMed Central: [PMC7233399](https://pubmed.ncbi.nlm.nih.gov/PMC7233399/)].
- Adams ER, Ainsworth M, Anand R, Andersson MI, Auckland K, Baillie JK, et al. Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. *Wellcome Open Res*. 2020;5:139. doi: [10.12688/wellcomeopenres.15927.1](https://doi.org/10.12688/wellcomeopenres.15927.1). [PubMed: [33748431](https://pubmed.ncbi.nlm.nih.gov/33748431/)]. [PubMed Central: [PMC7941096](https://pubmed.ncbi.nlm.nih.gov/PMC7941096/)].
- Cassaniti I, Novazzi F, Giardina F, Salinaro F, Sachs M, Perlini S, et al. Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. *J Med Virol*. 2020;92(10):1724-7. doi: [10.1002/jmv.25800](https://doi.org/10.1002/jmv.25800). [PubMed: [32227490](https://pubmed.ncbi.nlm.nih.gov/32227490/)]. [PubMed Central: [PMC7228409](https://pubmed.ncbi.nlm.nih.gov/PMC7228409/)].

14. Virgilio Paradiso A, De Summa S, Loconsole D, Procacci V, Sallustio A, Centrone F, et al. Clinical meanings of rapid serological assay in patients tested for SARS-Co2 RT-PCR. *medRxiv*. 2020. doi: [10.1101/2020.04.03.20052183](https://doi.org/10.1101/2020.04.03.20052183).
15. Perez-Garcia F, Perez-Tanoira R, Romanyk J, Arroyo T, Gomez-Herruz P, Cuadros-Gonzalez J. Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: A prospective single-center study. *J Clin Virol*. 2020;**129**:104473. doi: [10.1016/j.jcv.2020.104473](https://doi.org/10.1016/j.jcv.2020.104473). [PubMed: [32504945](https://pubmed.ncbi.nlm.nih.gov/32504945/)]. [PubMed Central: [PMC7255149](https://pubmed.ncbi.nlm.nih.gov/PMC7255149/)].
16. Liu Y, Li Z, Yi Y, Luo X, Xiong N, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *J Med Virol*. 2020;**92**(9):1518–24. doi: [10.1002/jmv.25727](https://doi.org/10.1002/jmv.25727). [PubMed: [32104917](https://pubmed.ncbi.nlm.nih.gov/32104917/)]. [PubMed Central: [PMC7228300](https://pubmed.ncbi.nlm.nih.gov/PMC7228300/)].
17. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. *Clin Infect Dis*. 2020;**71**(16):2027–34. doi: [10.1093/cid/ciaa344](https://doi.org/10.1093/cid/ciaa344). [PubMed: [32221519](https://pubmed.ncbi.nlm.nih.gov/32221519/)]. [PubMed Central: [PMC7184337](https://pubmed.ncbi.nlm.nih.gov/PMC7184337/)].
18. Lou B, Li TD, Zheng SF, Su YY, Li ZY, Liu W, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. *Eur Respir J*. 2020;**56**(2). doi: [10.1183/13993003.00763-2020](https://doi.org/10.1183/13993003.00763-2020). [PubMed: [32430429](https://pubmed.ncbi.nlm.nih.gov/32430429/)]. [PubMed Central: [PMC7401320](https://pubmed.ncbi.nlm.nih.gov/PMC7401320/)].
19. Guo L, Ren L, Yang S, Xiao M, Yang F, Chang, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis*. 2020;**71**(15):778–85. doi: [10.1093/cid/ciaa310](https://doi.org/10.1093/cid/ciaa310). [PubMed: [32198501](https://pubmed.ncbi.nlm.nih.gov/32198501/)]. [PubMed Central: [PMC7184472](https://pubmed.ncbi.nlm.nih.gov/PMC7184472/)].
20. Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M, et al. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. *J Med Virol*. 2020;**92**(9):1671–5. doi: [10.1002/jmv.25932](https://doi.org/10.1002/jmv.25932). [PubMed: [32330291](https://pubmed.ncbi.nlm.nih.gov/32330291/)]. [PubMed Central: [PMC7264663](https://pubmed.ncbi.nlm.nih.gov/PMC7264663/)].
21. Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. *Int J Infect Dis*. 2020;**94**:49–52. doi: [10.1016/j.ijid.2020.03.065](https://doi.org/10.1016/j.ijid.2020.03.065). [PubMed: [32251798](https://pubmed.ncbi.nlm.nih.gov/32251798/)]. [PubMed Central: [PMC7194885](https://pubmed.ncbi.nlm.nih.gov/PMC7194885/)].
22. Cai X, Chen J, Hu J, Long Q, Deng H, Fan K, et al. A Peptide-based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Corona Virus Disease 2019 (COVID-19). *medRxiv*. 2020. doi: [10.1101/2020.02.22.20026617](https://doi.org/10.1101/2020.02.22.20026617).
23. Xie J, Ding C, Li J, Wang Y, Guo H, Lu Z, et al. Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test. *J Med Virol*. 2020;**92**(10):2004–10. doi: [10.1002/jmv.25930](https://doi.org/10.1002/jmv.25930). [PubMed: [32330303](https://pubmed.ncbi.nlm.nih.gov/32330303/)]. [PubMed Central: [PMC7264659](https://pubmed.ncbi.nlm.nih.gov/PMC7264659/)].
24. Yangchun F. Optimize Clinical Laboratory Diagnosis of COVID-19 from Suspect Cases by Likelihood Ratio of SARS-CoV-2 IgM and IgG antibody. *medrxiv*. 2020. doi: [10.1101/2020.04.07.20053660](https://doi.org/10.1101/2020.04.07.20053660).
25. Qian C, Zhou M, Cheng F, Lin X, Gong Y, Xie X, et al. Development and Multicenter Performance Evaluation of The First Fully Automated SARS-CoV-2 IgM and IgG Immunoassays. *medRxiv*. 2020. doi: [10.1101/2020.04.16.20067231](https://doi.org/10.1101/2020.04.16.20067231).
26. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. *Radiology*. 2020;**296**(2):115–7. doi: [10.1148/radiol.20200432](https://doi.org/10.1148/radiol.20200432). [PubMed: [32073353](https://pubmed.ncbi.nlm.nih.gov/32073353/)]. [PubMed Central: [PMC7233365](https://pubmed.ncbi.nlm.nih.gov/PMC7233365/)].
27. Ruch Y, Kaeuffer C, Ohana M, Labani A, Fabacher T, Bilbault P, et al. CT lung lesions as predictors of early death or ICU admission in COVID-19 patients. *Clin Microbiol Infect*. 2020;**26**(10):1417 e5–8. doi: [10.1016/j.cmi.2020.07.030](https://doi.org/10.1016/j.cmi.2020.07.030). [PubMed: [32717417](https://pubmed.ncbi.nlm.nih.gov/32717417/)]. [PubMed Central: [PMC7378475](https://pubmed.ncbi.nlm.nih.gov/PMC7378475/)].
28. Xiang C, Lu L, Zhou J, Guan L, Yang C, Chai CC. Findings in a Novel Coronavirus Disease (COVID-19) Pneumonia at Initial Presentation. *BioMed Res Int*. 2020:1–10.
29. Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, et al. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. *Radiology*. 2020;**296**(2):E55–64. doi: [10.1148/radiol.202000843](https://doi.org/10.1148/radiol.202000843). [PubMed: [32191587](https://pubmed.ncbi.nlm.nih.gov/32191587/)]. [PubMed Central: [PMC7233482](https://pubmed.ncbi.nlm.nih.gov/PMC7233482/)].
30. Du S, Gao S, Huang G, Li S, Chong W, Jia Z, et al. Chest lesion CT radiological features and quantitative analysis in RT-PCR turned negative and clinical symptoms resolved COVID-19 patients. *Quant Imaging Med Surg*. 2020;**10**(6):1307–17. doi: [10.21037/qims-20-531](https://doi.org/10.21037/qims-20-531). [PubMed: [32550139](https://pubmed.ncbi.nlm.nih.gov/32550139/)]. [PubMed Central: [PMC7276361](https://pubmed.ncbi.nlm.nih.gov/PMC7276361/)].
31. Rousan LA, Elobeid E, Karrar M, Khader Y. Chest x-ray findings and temporal lung changes in patients with COVID-19 pneumonia. *BMC Pulm Med*. 2020;**20**(1):2–11. doi: [10.1186/s12890-020-01286-5](https://doi.org/10.1186/s12890-020-01286-5). [PubMed: [32933519](https://pubmed.ncbi.nlm.nih.gov/32933519/)]. [PubMed Central: [PMC7491017](https://pubmed.ncbi.nlm.nih.gov/PMC7491017/)].
32. Shabrawishi M, Al-Gethamy MM, Naser AY, Ghazawi MA, Alsharif GF, Obaid EF, et al. Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. *PLoS One*. 2020;**15**(8):2–11.
33. Werberich GM, Marchiori E, Barreto MM, Rodrigues RS. Computed tomography findings in a Brazilian cohort of 48 patients with pneumonia due to coronavirus disease. *J Braz Soc Trop Med*. 2020;**53**(4):1–7. doi: [10.1590/0037-8682-0405-2020](https://doi.org/10.1590/0037-8682-0405-2020). [PubMed: [32696812](https://pubmed.ncbi.nlm.nih.gov/32696812/)]. [PubMed Central: [PMC7375798](https://pubmed.ncbi.nlm.nih.gov/PMC7375798/)].
34. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. *Radiology*. 2020;**295**(3):685–91. doi: [10.1148/radiol.202000463](https://doi.org/10.1148/radiol.202000463). [PubMed: [32077789](https://pubmed.ncbi.nlm.nih.gov/32077789/)]. [PubMed Central: [PMC7233369](https://pubmed.ncbi.nlm.nih.gov/PMC7233369/)].
35. Wu J, Wu X, Zeng W, Guo D, Fang Z, Chen L, et al. Chest CT Findings in Patients With Coronavirus Disease 2019 and Its Relationship With Clinical Features. *Invest Radiol*. 2020;**55**(5):257–61. doi: [10.1097/RLI.0000000000000670](https://doi.org/10.1097/RLI.0000000000000670). [PubMed: [32091414](https://pubmed.ncbi.nlm.nih.gov/32091414/)]. [PubMed Central: [PMC7147284](https://pubmed.ncbi.nlm.nih.gov/PMC7147284/)].
36. Xu X, Yu C, Zhang L, Luo L, Liu J. Imaging features of 2019 novel coronavirus pneumonia. *Eur J Nucl Med Mol Imaging*. 2020;**47**(5):1022–3. doi: [10.1007/s00259-020-04720-2](https://doi.org/10.1007/s00259-020-04720-2). [PubMed: [32060619](https://pubmed.ncbi.nlm.nih.gov/32060619/)]. [PubMed Central: [PMC7079932](https://pubmed.ncbi.nlm.nih.gov/PMC7079932/)].
37. Cui N, Zou X, Xu L. Preliminary CT findings of coronavirus disease 2019 (COVID-19). *Clin Imaging*. 2020;**65**:124–32. doi: [10.1016/j.clinimag.2020.04.042](https://doi.org/10.1016/j.clinimag.2020.04.042). [PubMed: [32464579](https://pubmed.ncbi.nlm.nih.gov/32464579/)]. [PubMed Central: [PMC7214302](https://pubmed.ncbi.nlm.nih.gov/PMC7214302/)].
38. Falaschi Z, Danna PSC, Arioli R, Pasche A, Zagaria D, Percivale I, et al. Chest CT accuracy in diagnosing COVID-19 during the peak of the Italian epidemic: A retrospective correlation with RT-PCR testing and analysis of discordant cases. *Eur J Radiol*. 2020;**130**:109192. doi: [10.1016/j.ejrad.2020.109192](https://doi.org/10.1016/j.ejrad.2020.109192). [PubMed: [32738464](https://pubmed.ncbi.nlm.nih.gov/32738464/)]. [PubMed Central: [PMC7382359](https://pubmed.ncbi.nlm.nih.gov/PMC7382359/)].
39. Imai K, Tabata S, Ikeda M, Noguchi S, Kitagawa Y, Matuoka M, et al. Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19. *J Clin Virol*. 2020;**128**:104393. doi: [10.1016/j.jcv.2020.104393](https://doi.org/10.1016/j.jcv.2020.104393). [PubMed: [32387968](https://pubmed.ncbi.nlm.nih.gov/32387968/)]. [PubMed Central: [PMC7191278](https://pubmed.ncbi.nlm.nih.gov/PMC7191278/)].
40. Wei W, Ling W, Yangchun X, Qiang W. Knockdown of long non-coding RNA GHET1 suppresses cervical carcinoma in vitro and in vivo. *Cancer Biomark*. 2020;**28**(1):21–32. doi: [10.3233/CBM-190269](https://doi.org/10.3233/CBM-190269). [PubMed: [32176622](https://pubmed.ncbi.nlm.nih.gov/32176622/)].
41. Parry AH, Wani AH, Yaseen M, Dar KA, Choh NA, Khan NA, et al. Spectrum of chest computed tomographic (CT) findings in coronavirus disease-19 (COVID-19) patients in India. *Eur J Radiol*. 2020;**129**:109147. doi: [10.1016/j.ejrad.2020.109147](https://doi.org/10.1016/j.ejrad.2020.109147). [PubMed: [32623113](https://pubmed.ncbi.nlm.nih.gov/32623113/)]. [PubMed Central: [PMC7313528](https://pubmed.ncbi.nlm.nih.gov/PMC7313528/)].
42. Goldberg-Stein S, Fink A, Paroder V, Kobi M, Yee J, Chernyak V. Abdominopelvic CT findings in patients with novel coronavirus disease 2019 (COVID-19). *Abdom Radiol (NY)*. 2020;**45**(9):2613–23. doi: [10.1007/s00261-020-01286-5](https://doi.org/10.1007/s00261-020-01286-5).

- 10.1007/s00261-020-02669-2. [PubMed: 32761402]. [PubMed Central: PMC7406871].
43. Gu Q, Ouyang X, Xie A, Tan X, Liu J, Huang F, et al. A retrospective study of the initial chest CT imaging findings in 50 COVID-19 patients stratified by gender and age. *J Xray Sci Technol.* 2020;28(5):875–84. doi: 10.3233/XST-200709. [PubMed: 32804112]. [PubMed Central: PMC7592672].
 44. Meiler S, Schaible J, Poschenrieder F, Scharf G, Zeman F, Rennert J, et al. Can CT performed in the early disease phase predict outcome of patients with COVID 19 pneumonia? Analysis of a cohort of 64 patients from Germany. *Eur J Radiol.* 2020;131:109256. doi: 10.1016/j.ejrad.2020.109256. [PubMed: 32919265]. [PubMed Central: PMC7452844].
 45. Brendish NJ, Poole S, Naidu VV, Mansbridge CT, Norton NJ, Wheeler H, et al. Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study. *Lancet Respir Med.* 2020;8(12):1192–200. doi: 10.1016/s2213-2600(20)30454-9.
 46. Butt AM, Siddique S, An X, Tong Y. Development of a dual-gene loop-mediated isothermal amplification (LAMP) detection assay for SARS-CoV-2: A preliminary study. *medRxiv.* 2020. doi: 10.1101/2020.04.08.20056986.
 47. Haq F, Sharif S, Khurshid A, Shabbir I, Salman M, Badar N, et al. Development Optimization and Validation of RT-LAMP based COVID-19 Facility in Pakistan. *bioRxiv.* 2020. doi: 10.1101/2020.05.29.124123.
 48. Mohon AN, Hundt J, van Marle G, Pabbaraju K, Berenger B, Griener T, et al. Development and validation of direct RT-LAMP for SARS-CoV-2. *medRxiv.* 2020. doi: 10.1101/2020.04.29.20075747.
 49. Ghofrani M, Casas MT, Pelz RK, Kroll C, Blum N, Foster SD. Performance characteristics of the ID NOW COVID 19 assay: A regional health care system experience. *medRxiv.* 2020. doi: 10.1101/2020.06.03.20116327.
 50. Smithgall MC, Scherberkova I, Whittier S, Green DA. Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2. *J Clin Virol.* 2020;128:104428. doi: 10.1016/j.jcv.2020.104428. [PubMed: 32434706]. [PubMed Central: PMC7217789].
 51. Bulterys PL, Garamani N, Stevens B, Sahoo MK, Huang C, Hogan CA, et al. Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2. *J Clin Virol.* 2020;129:104427. doi: 10.1016/j.jcv.2020.104427. [PubMed: 32535398]. [PubMed Central: PMC7207111].
 52. Zhang H, Jiang XJ, Liu XH, Ma H, Zhang YH, Rao Y, et al. Chest computed tomography (CT) findings and semiquantitative scoring of 60 patients with coronavirus disease 2019 (COVID-19): A retrospective imaging analysis combining anatomy and pathology. *PLoS One.* 2020;15(9). e0238760. doi: 10.1371/journal.pone.0238760. [PubMed: 32886711]. [PubMed Central: PMC7473568].
 53. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis.* 2020;20(4):425–34. doi: 10.1016/s1473-3099(20)30086-4.
 54. Cheng Z, Lu Y, Cao Q, Qin L, Pan Z, Yan F, et al. Clinical Features and Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) in a Single-Center Study in Shanghai, China. *AJR Am J Roentgenol.* 2020;215(1):121–6. doi: 10.2214/AJR.20.22959. [PubMed: 32174128].
 55. Van Elslande J, Houben E, Depypere M, Brackenier A, Desmet S, Andre E, et al. Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. *Clin Microbiol Infect.* 2020;26(8):1082–7. doi: 10.1016/j.cmi.2020.05.023. [PubMed: 32473953]. [PubMed Central: PMC7255746].
 56. Huang S, Lin C, Yan M, Li H, Liu T, Michael W, et al. Rapid Detection of COVID-19 by Serological Methods and the Evaluation of Diagnostic Efficacy of IgM and IgG. *Clin Lab.* 2020;66(11/2020). doi: 10.7754/Clin.Lab.2020.200617.
 57. Nie W, Feng Z, Mao X, Rong P, Wang W, Liang Q. First CT characteristic appearance of patients with coronavirus disease 2019. *J Cent South Univ Med Sci.* 2020;45(3):262–8.
 58. Ying L, Yue-ping L, Bo D, Feifei R, Yue W, Jinya D, et al. Diagnostic Indexes of a Rapid IgG/IgM Combined Antibody Test for SARS-CoV-2. *medRxiv.* 2020. doi: 10.1101/2020.03.26.20044883.
 59. Hueston L, Kok J, Guibone A, McDonald D, Hone G, Goodwin J, et al. The Antibody Response to SARS-CoV-2 Infection. *Open Forum Infect Dis.* 2020;7(9):ofaa387. doi: 10.1093/ofid/ofaa387. [PubMed: 32989419]. [PubMed Central: PMC7499696].
 60. Göncü B. Protein-based Approaches for the Diagnosis of COVID-19. *J Adv Res Health Sci.* 2020;3(1):31–9.
 61. General Office of National Health Committee. [Notice on the issuance of a program for the diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (trial sixth edition)]. General Office of National Health Committee; 2020, [cited 18/11/2020]. Chinese. Available from: <http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2>.
 62. Xu B, Xing Y, Peng J, Zheng Z, Tang W, Sun Y, et al. Chest CT for detecting COVID-19: a systematic review and meta-analysis of diagnostic accuracy. *Eur Radiol.* 2020;30(10):5720–7. doi: 10.1007/s00330-020-06934-2. [PubMed: 32415585]. [PubMed Central: PMC7227176].
 63. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical Coronavirus Disease 2019 (COVID-19) Pneumonia: Relationship to Negative RT-PCR Testing. *Radiology.* 2020;296(2):E41–5. doi: 10.1148/radiol.2020200343. [PubMed: 32049601]. [PubMed Central: PMC7233363].
 64. British Society of Thoracic Imaging. *Radiology Decision Tool for Suspected COVID-19.* London, UK: British Society of Thoracic Imaging; 2020.

Table 2. Characteristics of the Studies Included in the Meta-analysis

| Study | Country | COVID-19 Laboratory Diagnosis Method | Sample | Total Number of Tests (N) | Number of Tests That Were Positive with PCR (N) | Number of Patients Who Tested Positive with CT, ELISA and POC Tests (N) | Qualitative Score |
|-------------------------------|--------------|--------------------------------------|---------------------|---------------------------|---|---|-------------------|
| Ai et al. (11) | China | CT | Throat swab | 1014 | 601 | 580 | 11 |
| Adams et al. (12) | ABD | ELISA | Blood | 142 | 40 | 34 | 10 |
| Cassaniti et al. (13) | Italy | POC | Blood | 50 | 41 | 7 | 4 |
| Virgilio Paradiso et al. (14) | Italy | POC | Blood | 191 | 70 | 33 | 5 |
| Perez-Garcia et al. (15) | Spain | POC | Blood | 90 | 55 | 26 | 4 |
| Liu et al. (16) | China | POC | Pharyngeal swab | 179 | 90 | 77 | 8 |
| Zhao et al. (17) | China | ELISA | Blood | 173 | 173 | 161 | 11 |
| Lou et al. (18) | China | ELISA | Blood | 80 | 80 | 79 | 10 |
| Guo et al. (19) | China | ELISA | Blood | 82 | 82 | 65 | 8 |
| Infantino et al. (20) | Italy | ELISA | Nasopharyngeal swab | 64 | 64 | 41 | 7 |
| Jin et al. (21) | China | ELISA | Sputum/oral swab | 76 | 27 | 24 | 9 |
| Cai et al. (22) | China | ELISA | Oral swab | 276 | 276 | 225 | 10 |
| Xie et al. (23) | China | ELISA | Blood | 56 | 16 | 15 | 10 |
| Yangchun et al. (24) | China | ELISA | Blood | 284 | 205 | 197 | 11 |
| Qian et al. (25) | China | ELISA | Blood | 972 | 503 | 486 | 12 |
| Fang et al. (26) | China | CT | Throat swab | 81 | 51 | 50 | 9 |
| Ruch et al. (27) | Fransa | CT | Unspecified | 572 | 572 | 558 | 11 |
| Xiang et al. (28) | China | CT | Unspecified | 83 | 53 | 50 | 8 |
| Wang et al. (29) | China | CT | Unspecified | 107 | 90 | 50 | 7 |
| Du et al. (30) | China | CT | Unspecified | 125 | 125 | 99 | 9 |
| Rousan et al. (31) | Jordan | CT | Nasopharyngeal swab | 88 | 88 | 75 | 7 |
| Shabrawishi et al. (32) | Saudi Arabia | CT | Unspecified | 150 | 150 | 119 | 8 |
| Werberich et al. (33) | Brasil | CT | Unspecified | 78 | 78 | 48 | 6 |
| Bernheim et al. (34) | China | CT | Unspecified | 121 | 121 | 94 | 8 |
| Wu et al. (35) | China | CT | Unspecified | 80 | 80 | 73 | 8 |
| Xu et al. (36) | China | CT | Unspecified | 90 | 90 | 69 | 8 |
| Cui et al. (37) | China | CT | Unspecified | 95 | 95 | 53 | 7 |
| Falascchi et al. (38) | Italy | CT | Unspecified | 773 | 462 | 419 | 11 |

| | | | | | | | |
|-----------------------------------|----------------------|-------|------------------------------------|-----|-----|-----|----|
| Imai et al. (39) | Japan | POC | Blood | 112 | 112 | 37 | 5 |
| Wei et al. (40) | China | CT | Unspecified | 163 | 163 | 145 | 7 |
| Parry et al. (41) | India | CT | Unspecified | 147 | 147 | 51 | 7 |
| Goldberg-Stein et al. (42) | ABD | CT | Nasal swab | 141 | 141 | 80 | 7 |
| Gu et al. (43) | China | CT | Nasopharyngeal, oropharyngeal swab | 50 | 50 | 38 | 8 |
| Meiler et al. (44) | Germany | CT | Unspecified | 64 | 64 | 62 | 7 |
| Brendish et al. (45) | United Arab Emirates | POC | Nasal swab | 517 | 499 | 157 | 6 |
| Imai et al. (39) | Japan | CT | Blood | 112 | 112 | 77 | 8 |
| Butt et al. (46) | Pakistan | POC | Nasopharyngeal swab | 70 | 45 | 43 | 8 |
| Haq et al. (47) | India | POC | Nasopharyngeal swab | 84 | 72 | 62 | 7 |
| Mohon et al. (48) | Canada | POC | Nasopharyngeal swab | 120 | 42 | 41 | 9 |
| Poon L.I.M., et al. 2020 | China | POC | Nasopharyngeal swab | 78 | 12 | 12 | 8 |
| Ghofrani et al. (49) | ABD | POC | Nasal swab/nasopharyngeal swab | 112 | 17 | 16 | 9 |
| Smithgall et al. (50) | ABD | POC | Nasal swab/nasopharyngeal swab | 113 | 113 | 84 | 7 |
| Bulterys et al. (51) | ABD | POC | Nasal swab/nasopharyngeal swab | 80 | 29 | 24 | 7 |
| Zhang et al. (52) | China | CT | Unspecified | 60 | 60 | 48 | 8 |
| Shi et al. (53) | China | CT | Unspecified | 81 | 81 | 66 | 8 |
| Cheng et al. (54) | China | CT | Unspecified | 53 | 11 | 11 | 9 |
| Elslande et al. (55) | Belgium | ELISA | Blood | 103 | 94 | 86 | 11 |
| Huang et al. (56) | China | ELISA | Throat swab | 82 | 63 | 55 | 9 |